Biotech M&A Targets in 2026: Where Pharma Is Really Buying

The short answer: In H1 2026, pharma spent most of its M&A capital on oncology (41% of deal value) and immunology (19%), with neurology, women's health and rare disease filling out the top five, according to IQVIA. Cardiovascular-renal-metabolic (CVRM), the #2 area in 2025, dropped out of the top five. Buyers are paying for differentiated platforms and de-risked clinical data, and they are sourcing aggressively from China and Europe alongside the US.

If you run BD, M&A or corporate venture capital, the biotech M&A targets 2026 buyers chose tell you where competition for assets is fiercest, and where you can still find value.

How big is biotech M&A in 2026 so far?

Big. IQVIA counts 42 biopharma M&A deals worth about $130B in H1 2026, almost matching the full-year total for 2025. Average deal size reached $3.1B, the second highest since 2021. BioBucks, using a broader definition of control transactions, tracks roughly $149B across 49 deals in H1, with Q2 alone at about $105B. Counts differ by methodology; the direction does not.

PwC frames the driver plainly: more than $300B of branded pharma revenue faces loss of exclusivity this decade, which keeps big pharma in portfolio-replenishment mode. PwC expects deal momentum to continue through the second half of 2026.

The headline deals set the tone: Sun Pharma/Organon ($11.8B), AbbVie/Apogee ($10.9B), GSK/Nuvalent ($10.6B), and Eli Lilly, which BioSpace reports spent about $25B across nine deals in H1.

Which therapeutic areas are pharma buyers paying for?

BioBucks' value breakdown points the same way: oncology ($46.1B) and immunology and inflammation ($31.6B) lead, followed by specialty pharma and neuroscience.

The CVRM drop deserves care. It reflects M&A value, not interest. Obesity and metabolic assets still feature heavily in licensing, per PwC and the BioBucks BD&L tracker. Buyers appear to prefer licensing structures over outright acquisitions in this space for now.

Which modalities are attracting the money?

IQVIA highlights the platform bets inside Lilly's deal run: gene therapies, in vivo CAR-T, multi-specifics, T-cell engagers and ADCs. The wider market confirms the pattern.

Every modality in that table carries elevated CMC risk. That is where deals slow down or reprice.

How important is China, and where does the US-Europe corridor fit?

China is now a core sourcing channel. Reuters, citing CCTV and NMPA data, reports that China's innovative drug out-licensing deals reached about $110B across 81 deals in H1 2026, a record. IQVIA puts in-licensing of Chinese-originated assets at $92B, or 88% of the 2025 total. Licensees came mainly from the US, Britain, France and Italy.

The US-Europe corridor runs both ways. In spring 2026, mid-sized European companies bought US biotechs at pace: Angelini/Catalyst ($4.1B), Servier/Day One ($2.5B), UCB/Candid ($2.2B) and Chiesi/KalVista ($1.9B). Meanwhile US acquirers reached into Europe, as Gilead's purchase of Munich-based Tubulis shows.

Where do European biotech assets fit?

European biotech assets for licensing offer three things buyers want in 2026.

The catch: European assets are often under-packaged for US buyers. Data rooms are built for EMA conversations, CMC documentation is thin, and the US regulatory strategy is undefined. PXM sources and packages these assets through Scout and closes licensing and M&A through Transact.

What red flags should buyers check in due diligence?

CMC is where good science fails. PharmTech, analysing FDA's published complete response letters, reports that 74% of CRLs issued from 2020 to 2024 cited quality or manufacturing deficiencies. Use this biotech due diligence checklist before you sign a term sheet.

Due-diligence red-flag checklist

• Tech transfer gaps: process parameters, raw materials or equipment differ between clinical and planned commercial sites, with no bridging data.
• Missing comparability: no comparability protocol for process or site changes; assay formats changed between phases without validation.
• Documentation holes: batch records, development reports or deviation logs incomplete or held only by the CDMO.
• Weak traceability: starting materials, cell banks or vectors without full chain of custody and supplier qualification.
• Potency assay risk: no clear link between the potency assay and clinical mechanism; LOD/LOQ unjustified.
• Single-source supply: one CDMO or one critical reagent supplier, with no backup or exit terms.
• Regulatory pathway assumed, not tested: no FDA or EMA scientific advice on the pivotal design.
• IP misaligned with the product: composition claims that do not cover the clinical formulation or manufacturing process.
• Clinical data not decision-grade: small, open-label or single-site data presented as proof of differentiation.

The PXM Score structures this review across six dimensions: Science, Regulatory Pathway, Clinical Strategy, CMC & Manufacturability, IP & Differentiation, and Market & Capital Fit. It surfaces deal-breaking gaps early, before you have spent months on a process.

How should buyers act on this in Q4 2026?

Competition is highest in oncology and immunology, and in platform modalities. To find value:

Investors and corporate venture capital teams in life sciences can see how PXM works with buyers at For Investors.

FAQ

What are the top biotech M&A targets in 2026?
By H1 2026 value, oncology (41%), immunology (19%), neurology (9%), women's health (9%) and rare disease (7%), per IQVIA. ADCs, cell therapy, in vivo CAR-T, multi-specifics, T-cell engagers and gene therapy are the most active modalities.

Why did cardiometabolic drop in 2026 M&A rankings?
IQVIA shows CVRM fell out of the top five by M&A value after ranking #2 in 2025. Activity has not disappeared: obesity and metabolic assets remain prominent in licensing deals, often in-licensed from China.

Are European biotech assets good licensing targets?
Yes, if packaged correctly. They often offer strong science at lower valuations and diversify China exposure. Buyers should expect gaps in CMC documentation and US regulatory strategy and budget to close them.

What is the most common due-diligence red flag?
CMC. Tech transfer gaps, missing comparability data and weak documentation recur in FDA complete response letters and delay or reprice deals.

Looking for in-licensing or acquisition targets? Tell PXM what you are looking for.

Sources